VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder Oct 14, 2021
VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B’s Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain Oct 5, 2021
VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2 Sep 13, 2021
VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update Aug 12, 2021
VistaGen Therapeutics to Report Fiscal Year 2022 First Quarter Financial Results and Host Conference Call and Webcast on August 12, 2021 Aug 9, 2021
VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors Jul 22, 2021
